All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.

  TRANSLATE

The SOT Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the SOT Hub cannot guarantee the accuracy of translated content. The SOT Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The SOT Hub is an independent medical education platform, supported through a founding grant from Therakos. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Drug updates

VIEW ALL
Important announcement
@US_FDA grants clearance under an investigational new drug application to proceed with the EXPRESS trial, which will evaluate a porcine-derived heart with 10 gene edits in adults aged ≥50 years with end-stage or advanced heart failure and no remaining therapeutic options. Read more: https://bwnews.pr/3PtBGJO
Important announcement
An industry-leading controlled hypothermic cardiac transport system receives a technology upgrade featuring a next-generation thermal control system designed to maintain temperatures of 4–8°C over extended durations. Read more: https://bit.ly/48gvM4R
Important announcement
🚨NEWS🚨 @US_FDA grants orphan drug designation to pegrizeprument, a novel investigational maintenance immunosuppressive agent, for the prevention of heart allograft rejection in patients receiving a #HeartTransplant. Read more: https://bit.ly/4sUZGD8